InsiderSignal.AI

InsiderSignal.ai

LLY - Eli Lilly & Co

Insider Purchase by Skovronsky Daniel (EVP, CSO, Pres LRL, LLY Imm)

1 Year
After Trade
Before Trade

Loading data...

Trade Summary

6 months ago, Skovronsky Daniel, serving as EVP, CSO, Pres LRL, LLY Imm at Eli Lilly & Co (LLY), purchased 1,000 shares at $634.41 per share, for a total transaction value of $634,405.00. Following this transaction, Skovronsky Daniel now holds 213,276 shares of LLY.

The trade was executed on Tuesday, August 12, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, August 12, 2025, meaning the disclosure happened on the same day as the trade.

Eli Lilly & Co operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - GENERAL industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Skovronsky Daniel

EVP, CSO, Pres LRL, LLY Imm

Daniel M. Skovronsky, M.D., Ph.D. is the chief scientific officer and executive vice president of science and technology at Eli Lilly and Company (LLY), where he also serves as president of Lilly Research Laboratories and president of Lilly Immunology, overseeing global business development.[[1]](https://schaeffer.usc.edu/people/daniel-m-skovronsky-md-phd/)[[2]](https://www.lilly.com/about/leadership/daniel-skovronsky) Skovronsky founded Avid Radiopharmaceuticals in 2004 while a graduate student at the University of Pennsylvania, developing diagnostic technologies for early Alzheimer's detection, and joined Lilly in 2010 following its acquisition of the company.[[1]](https://schaeffer.usc.edu/people/daniel-m-skovronsky-md-phd/)[[2]](https://www.lilly.com/about/leadership/daniel-skovronsky)[[3]](https://www.allamericanspeakers.com/speakers/466921/Daniel-Skovronsky) At Lilly, he advanced through roles including chief medical officer, vice president of tailored therapeutics and diabetes research, and senior vice president of clinical and product development, contributing to approvals of drugs like tirzepatide for obesity, donanemab for Alzheimer’s, and COVID-19 antibody therapies.[[3]](https://www.allamericanspeakers.com/speakers/466921/Daniel-Skovronsky)[[5]](https://biotechsuccess.com/daniel-skovronskys-leadership-principles/) He earned his B.S. in molecular biophysics and biochemistry from Yale University (1994), Ph.D. in neuroscience (2000), and M.D. from the Perelman School of Medicine at the University of Pennsylvania (2001), with residency in pathology and fellowship in neuropathology.[[2]](https://www.lilly.com/about/leadership/daniel-skovronsky)

View full insider profile →

Trade Price

$634.41

Quantity

1,000

Total Value

$634,405.00

Shares Owned

213,276

Trade Date

Tuesday, August 12, 2025

194 days ago

SEC Filing Date

Tuesday, August 12, 2025

HEALTHCAREDRUG MANUFACTURERS - GENERAL

About Eli Lilly & Co

Company Overview

No company information available
View news mentioning LLY

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/123231

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime